

#10

PATENT
Docket No.: 20011/1371

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Beck et al.

Serial No. : 09/704,306

Cnfrm. No. : 4919

Filed : November 2, 2000

For : NOVEL 4-PHENYL SUBSTITUTED
TETRAHYDROISOQUINOLINES AND USE
THEREOFExaminer:
To Be AssignedArt Unit:
1362

POWER TO INSPECT

U.S. Patent and Trademark Office
P.O. Box 2327
Arlington, VA 22202

Dear Sir:

Please permit Mike Surles, or his representative, to inspect the above-identified application, and to make any desired copies of papers from the subject application.

Respectfully submitted,

Date: June 4, 2002
Edwin V. Merkel
Registration No. 40,087NIXON PEABODY LLP
Clinton Square, P.O. Box 31051
Rochester, New York 14603
Telephone: (585) 263-1128
Facsimile: (585) 263-1600

#8

PATENT
Docket No.: 20011/1371

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants :	Beck et al.)	Examiner:
)	To Be Assigned
Serial No. :	09/704,306)	
)	Art Unit:
Cnfrm. No. :	4919)	1362
)	
Filed :	November 2, 2000)	
)	
For :	NOVEL 4-PHENYL SUBSTITUTED)	
	TETRAHYDROISOQUINOLINES AND USE)	
	THEREOF)	

REVOCATION AND POWER OF ATTORNEY

U.S. Patent and Trademark Office
Box 2327
Arlington, Virginia 22202
Box:

Dear Sir:

The undersigned assignee of the entire interest in the above-identified application for Letters Patent, Albany Molecular Research, Inc., hereby revokes all previous powers of attorney in the subject application and hereby appoints Michael L. Goldman, Registration No. 30,727; Joseph M. Noto, Registration No. 32,163; Gunnar G. Leinberg, Registration No. 35,584; Edwin V. Merkel, Registration No. 40,087; Georgia Evans, Registration No. 44,597; Alice Y. Choi, Registration No. 45,758; Andrew K. Gonsalves, Registration No. 48,145; Noreen L. Connolly, Registration No. 48,987; and John Campa, Registration No. 49,014 all with a mailing address of Nixon Peabody LLP, Clinton Square, P.O. Box 31051, Rochester, New York 14603, telephone number (585) 263-1000, as its attorneys with full power of substitution and revocation to prosecute this application and to transact all business in the U.S. Patent and Trademark Office connected herewith.

The undersigned assignee of the right, title and interest of the above-identified application, hereby confirms that an assignment from the inventors to DuPont

- 2 -

Pharmaceuticals Company for the subject application was recorded on May 21, 2001, at Reel 011831/Frame 0728 in the U.S. Patent and Trademark Office. A Change of Name Recordation from DuPont Pharmaceuticals Company to Bristol-Myers Squibb Pharma Company (copy enclosed) was filed on January 8, 2002. An assignment from Bristol-Myers Squibb Pharma Company to Albany Molecular Research, Inc. (copy enclosed) was filed with the U.S. Patent and Trademark Office on May 16, 2002.

The undersigned has reviewed all the documents in the chain of title of the patent application identified above and, to the best of the undersigned's knowledge and belief, title is in the assignee identified below.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Please direct all future communications relative to said application to the following correspondence address:

Michael L. Goldman
NIXON PEABODY LLP
Clinton Square, P.O. Box 31051
Rochester, New York 14603
Telephone: (585) 263-1304
Facsimile: (585) 263-1600

Respectfully submitted,

ALBANY MOLECULAR RESEARCH, INC.

Dated: May 20, 2002

By: Lawrence C. Jones
Lawrence C. Jones, Ph.D.

Albany Molecular Research, Inc.
21 Corporate Circle
P.O. Box 15098
Albany, New York 12212-5098
Telephone: (518) 464-0279
Facsimile: (518) 464-0289

Form PTO-1595 (Rev. 03/01) OMB No. 0651-0027 (exp. 5/31/2002) Tab settings		RECORDATION FORM COVER SHEET PATENTS ONLY		U.S. DEPARTMENT OF COMMERCE U.S. Patent and Trademark Office	
To the Honorable Commissioner of Patents and Trademarks: Please record the attached original documents or copy thereof.					
1. Name of conveying party(ies): DuPont Pharmaceuticals Company Additional name(s) of conveying party(ies) attached? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No			2. Name and address of receiving party(ies) Name: <u>Bristol-Myers Squibb Pharma Company</u> Internal Address: <u>Patent Department</u> Street Address: <u>P.O. Box 4000</u> City: <u>Princeton</u> State: <u>NJ</u> Zip: <u>08543-4000</u> Additional name(s) & address(es) attached? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		
3. Nature of conveyance: <input type="checkbox"/> Assignment <input type="checkbox"/> Merger <input type="checkbox"/> Security Agreement <input checked="" type="checkbox"/> Change of Name <input type="checkbox"/> Other _____ Execution Date: <u>10/01/2001</u>			4. Application number(s) or patent number(s): If this document is being filed together with a new application, the execution date of the application is: _____ A. Patent Application No.(s) _____ <u>See Schedule B attached</u> B. Patent No.(s) _____ <u>See Schedule A attached</u> Additional numbers attached? <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No		
5. Name and address of party to whom correspondence concerning document should be mailed: Name: <u>Denise Bierlein</u> Internal Address: <u>E353/133F</u> <u>Experimental Station</u> Street Address: <u>Route 141 & Henry Clay Road</u> City: <u>Wilmington</u> State: <u>DE</u> Zip: <u>19880-0353</u>			6. Total number of applications and patents involved: <u>614</u> 7. Total fee (37 CFR 3.41).....\$ <u>24,560.00</u> <input type="checkbox"/> Enclosed <input checked="" type="checkbox"/> Authorized to be charged to deposit account 8. Deposit account number: <u>023850</u>		
DO NOT USE THIS SPACE					
9. Signature. <div style="display: flex; justify-content: space-between; align-items: flex-end;"> <div style="text-align: center;"> <u>Denise M. Bierlein</u> Name of Person Signing </div> <div style="text-align: center;"> Signature </div> <div style="text-align: center;"> <u>January 8, 2002</u> Date </div> </div> <div style="text-align: right; margin-top: 10px;"> Total number of pages including cover sheet, attachments, and documents: <u>17</u> </div>					

PATENT**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE****CHANGE OF NAME IN RECORDED ASSIGNMENTS****1. Particulars of assignments**

A list of the patent applications and patents for which the change of name in the recorded assignment is requested is set forth in Schedule A (granted patents) and Schedule B (pending patent applications) attached hereto.

2. Old name of assignee

The old name of the assignee shown on the above-referenced assignments is DuPont Pharmaceuticals Company.

3. New name and address of assignee


The new name of the assignee is Bristol-Myers Squibb Pharma Company located at the following address: Patent Department, P.O. Box 4000, Princeton, NJ 08543-4000.

4. Proof of change of name

Proof of change of name is established by the attached certificate of name change from the following authority: Supplemental Certificate - New Castle County, Delaware

5. Payment of fee

Please refer to the RECORDATION FORM COVER SHEET, to which this paper is attached.


Blair Q. Ferguson
Reg. No. 34,329
Counsel, Intellectual Property
Experimental Station, E353/133C
Route 141 and Henry Clay Road
Wilmington, DE 19880-0353
Phone: 302/695-3902

NEW CASTLE COUNTY
REGISTRATION OF TRADE NAMES
PARTNERSHIPS & ASSOCIATIONS

TRADE NAME: Bristol-Myers Squibb Pharma Company (Original File No. 25757.0)

Business Address: 203 Longmeadow Drive, Wilmington, DE 19810

Telephone Number: _____

Title of Person, Firm or Association: Bristol-Myers Squibb Pharma Company

Names and addresses of all owners, members, or partners comprising the firm:

LAST NAME	FIRST NAME	ADDRESS
E.R. Squibb & Sons, L.L.C.		345 Park Ave., New York, NY 10154
Bristol-Myers Squibb Pharma Holding Company, LLC		345 Park Ave., New York, NY 10154

Date of ^{change} formation: October 2, 2001

Nature of ^{change} business: Title of partnership has changed from "DuPont Pharmaceutical Company" to "Bristol-Myers Squibb Pharma Company" and partners have changed from E.I. du Pont de Nemours and Company, Inc. to E.R. Squibb & Sons, L.L.C. and Bristol-Myers Squibb Pharma Holding Company, LLC

BEFORE ME, the subscriber, a Notary Public of the State of ~~Delaware~~ ^{New York}, personally appeared Sandra Leung, Secretary of Bristol-Myers Squibb Pharma Company, a principal in the business described in the foregoing Certificate, who, having first been sworn by me according to law did depose and say as follows:

1. He/She is a principal in the business described in the foregoing certificate.
2. That the foregoing information provided in the foregoing certificate is true, correct, and complete.

[Signature]
Affiant

SWORN AND SUBSCRIBED this 2nd day of October, 2001.

[Signature]
NOTARY PUBLIC

MAUREEN A. ROOB
Notary Public, State of New York
No. 01RO4826850
Qualified in Queens County
Commission Expires December 31, 2002

REV: 2/90

CERTIFIED AS A TRUE COPY.
ATTEST: SHARON AGNEW
PROTHONOTARY

[Signature]

RECORDATION FORM COVER SHEET

PATENTS ONLY

To the Director of the U.S. Patent and Trademark Office: Please record the attached original documents or copy thereof:

<p>1. Name of conveying party(ies):</p> <p>Bristol-Myers Squibb Pharma Company</p>	<p>2. Name and address of receiving party(ies):</p> <p>Albany Molecular Research, Inc. 21 Corporate Circle Albany, New York 12203-5154</p>
<p>3. Nature of conveyance:</p> <p><input checked="" type="checkbox"/> Assignment <input type="checkbox"/> Merger <input type="checkbox"/> Security Agreement <input type="checkbox"/> Change of Name <input type="checkbox"/> Other: _____</p> <p>Execution Date(s): March 15, 2002</p> <p>1st (sole) Inventor: 2nd Inventor: 3rd Inventor: 4th Inventor:</p>	
<p>4. Application number(s) or patent number(s): If this document is being filed together with a new application, the execution date(s) of the application is(are):</p> <p>1st (sole) Inventor: 2nd Inventor: 3rd Inventor: 4th Inventor:</p> <p>A. Patent Application No.(s): 09/704,306</p> <p>B. Patent No.(s):</p>	

5. Name and address of party to whom correspondence concerning document should be mailed:

Michael L. Goldman
NIXON PEABODY LLP
Clinton Square
P.O. Box 31051
Rochester, New York 14603-1051

6. Total number of applications and patents involved: 1

7. Total fee (37 CFR 3.41): \$40.00

☐ Previously paid (see original transmittal)

☒ A check in the amount of \$40.00 is enclosed.

8. Deposit Account Number: 14-1138

☐ Charge total fee to account.

☒ Charge any additional fees to account.

DO NOT USE THIS SPACE

9. Statement and signature.

To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document.

Date: May 16, 2002

Georgia Evans
Georgia Evans
Registration No. 44,597

[Total number of pages including cover sheet, attachments and document: 5]

Page 2 of 2

Certificate of Mailing - 37 CFR 1.8(a)

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:
U.S. Patent and Trademark Office P.O. BOX 2327
Arlington, VA 22202, on the date below.

Date: May 16, 2002 Ruth F. Smith
Ruth F. Smith

ATTACHMENT C**PATENT ASSIGNMENT**

WHEREAS, Bristol-Myers Squibb Pharma Company, a Delaware general partnership ("Assignor"), with its principal place of business at Route 141 and Henry Clay Road, Wilmington, Delaware 19880, U.S.A. is the owner of rights in the patent applications set forth on the attached Schedule 1, and the inventions disclosed and claimed therein (collectively, the "Patent Applications"); and

WHEREAS, Albany Molecular Research, Inc., a Delaware corporation ("Assignee"), with its principal place of business at 21 Corporate Circle, Albany, NY 12203-5154, U.S.A., desires to acquire the entire right, title, and interest in and to the Patent Applications;

WHEREAS, Assignor and Assignee are parties to a certain License Agreement, entered into as of the date of this assignment (the "License Agreement"), pursuant to which Assignor has agreed to assign to Assignee the Patent Applications;

NOW, THEREFORE, for good and valuable consideration, Assignor hereby sells, transfers, assigns, conveys, delivers, and sets over, and by these presents does hereby sell, transfer, assign, convey, deliver, and set over to said Assignee, the entire right, title and interest in and to said Patent Applications and all corresponding rights of priority under the International Convention for the Protection of Industrial Property, the Inter-American Convention Relating to Patent Applications, Designs and Industrial Models, and any other international agreements to which the United States adheres, the same to be held and enjoyed by said Assignee, its successors, assigns, nominees or legal representatives, as fully and entirely as the same would have been held and enjoyed by Assignor had this assignment, sale and transfer not been made;

AND ASSIGNOR hereby authorizes and requests the Commissioner of Patents and Trademarks of the United States and any official of any country or countries foreign to the United States whose duty it is to issue patents on the Patent Applications to issue to said Assignee, as assignee of the entire right, title and interest, any and all such patents.

ASSIGNOR hereby agrees to execute any papers and to perform such other proper acts as Assignee or its successors or assigns may deem reasonably necessary to secure to Assignee or to its successors or assigns, the rights hereby transferred.

WHEREFORE, Assignor has caused this Patent Assignment to be duly executed below, on the date indicated, by its duly authorized officer.

ASSIGNOR:

Bristol-Myers Squibb Pharma Company

By: Adam R.

Title: Secretary

Date: 3/15/02

Acknowledged and
Accepted:

ASSIGNEE:

Albany Molecular Research, Inc.

By: Thomas D'Ambra

Name: Thomas D'Ambra

Title: CEO

3/15/02